Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 31-year-old woman with a 5-year history of highly active relapsing-remitting multiple sclerosis is evaluated in the clinic. She has experienced recurrent clinical exacerbations, and a recent magnetic resonance imaging study of the brain and spine reveals multiple new gadolinium-enhancing lesions despite excellent adherence to sequential trials of dimethyl fumarate and natalizumab. After a comprehensive discussion of risks and benefits, she is transitioned to alemtuzumab. She completes baseline screening, receives prophylactic antiviral therapy, and finishes her first 5-day intravenous infusion course without severe acute infusion reactions. Prior to discharge, the physician must implement a strict, long-term monitoring protocol as mandated by the drug's Risk Evaluation and Mitigation Strategy (REMS) program to detect delayed, potentially life-threatening complications. Which of the following longitudinal monitoring parameters are strictly required for up to 48 months following her last infusion of this medication? (Select all that apply)

  1. Monthly complete blood count with differentialAnswer
  2. Monthly serum creatinine and urinalysis with microscopyAnswer
  3. Quarterly thyroid-stimulating hormone evaluationAnswer
  4. D
    Serial echocardiography every 6 months to assess left ventricular ejection fraction
  5. E
    Annual comprehensive ophthalmoscopy with optical coherence tomography
  6. F
    Monthly flow cytometry for CD4+ T-lymphocyte counts

Answer

The strictly required monitoring parameters for up to 48 months following alemtuzumab infusion are a monthly complete blood count with differential, monthly serum creatinine and urinalysis with microscopy, and a quarterly thyroid-stimulating hormone evaluation.
Alemtuzumab is a highly efficacious disease-modifying therapy for multiple sclerosis that functions by depleting CD52-expressing T and B lymphocytes. As the immune system reconstitutes over time, patients are at a severe, life-threatening risk of developing secondary autoimmune disorders. Because these conditions can manifest up to 4 years after the last dose, the FDA mandates a strict Risk Evaluation and Mitigation Strategy (REMS). This protocol explicitly requires monthly complete blood counts with differential to screen for immune thrombocytopenic purpura (ITP), monthly serum creatinine and urinalysis with microscopy to detect anti-glomerular basement membrane (anti-GBM) disease, and quarterly (every 3 months) thyroid-stimulating hormone (TSH) testing to monitor for autoimmune thyroid disorders. All three of these parameters must be tracked for 48 months following the last infusion.

Step-by-Step Solution

1
Identify the prescribed pharmacotherapy and its mechanism of action.
The patient is receiving alemtuzumab, a humanized monoclonal antibody targeting CD52, which causes profound and prolonged depletion of T and B lymphocytes.
Understanding the mechanism of action is essential to predicting the unique adverse effect profile during the immune reconstitution phase.
2
Determine the specific delayed adverse effects associated with this medication.
Alemtuzumab carries a significant risk for secondary autoimmune conditions, most notably immune thrombocytopenic purpura (ITP), anti-glomerular basement membrane (anti-GBM) disease, and autoimmune thyroiditis.
These complications can be fatal if not detected early, often presenting months to years after the final drug administration.
3
Apply the mandated Risk Evaluation and Mitigation Strategy (REMS) protocol guidelines for this high-risk medication.
The REMS program requires monthly blood counts (for ITP), monthly renal panels with urinalysis (for anti-GBM), and quarterly TSH testing (for thyroid disease) continuing for 48 months after the last dose.
Selecting the exact required intervals differentiates protocol-driven monitoring from standard periodic lab checks.

Key Concept

Alemtuzumab requires stringent, protocolized monitoring for up to 48 months post-infusion to detect secondary autoimmune complications: monthly CBC (for ITP), monthly urinalysis/creatinine (for anti-GBM disease), and quarterly TSH (for thyroiditis).
Estimated Time:2m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic